The Rights Issue Crossroads: Dilution, Discounts and the Choice Facing UK Shareholders
Photo: shareholder rights issue documents calculator pen financial newspaper UK, via myket.ir
UK companies have rediscovered the equity cheque. After a long stretch in which cheap debt and private capital did most of the work, more boards are asking existing shareholders to put fresh money into the business. The mechanism may be a rights issue, an open offer or a placing. The language in the announcement will be polished. The decision for a private investor is blunter: do you want to own more of this company on the terms being offered, or would you rather take the value of your entitlement and walk away?
Why the request arrives
A rights issue invites existing holders to buy new shares in proportion to their holding, usually at a discount. Pre-emption rights are meant to protect investors from silent dilution. An open offer offers similar participation, often to retail holders, but is not always fully pre-emptive. A placing sells shares to institutions and other buyers, frequently using the disapplication of pre-emption rights approved at the last annual meeting. In 2026, the UK market has become more comfortable with accelerated bookbuilds and placing-and-open-offer structures. That can be efficient for the company. It can also leave smaller shareholders watching from the touchline.
The arithmetic that matters
Take a simple example. You own 1,000 shares trading at 200p. The company announces a one-for-four rights issue at 120p. You are entitled to 250 new shares. Following your rights costs £300. The theoretical ex-rights price, or TERP, is the blended value of the old and new shares: four shares at 200p plus one at 120p, divided by five. That gives 184p. The 120p subscription price is a 40% discount to the old price, but only an 8% discount to the theoretical ex-rights price.
The nil paid right, the tradable entitlement to buy the new shares, is worth roughly 64p at the outset: 184p minus 120p. If you sell the rights, you keep your existing shares, now theoretically worth 184p each, and receive about £160 for the entitlement. Your total value is close to the pre-announcement £2,000, before costs and tax. If you follow, you invest £300 and own 1,250 shares at 184p, a holding worth £2,300. If you do nothing and let the rights lapse, you generally lose the value of the entitlement. That is the uncomfortable truth: a rights issue is not a windfall, and inaction is rarely neutral.
Follow, sell or take the cash
The first choice is whether the money is better deployed inside the company than outside it. Following a rights issue is not a loyalty test. It is a capital allocation decision. Ask what the new money does. If it funds a defined project with credible returns, or repairs a balance sheet before a refinancing, the case can be sound. If it merely plugs a hole that will reopen, the discount is not compensation.
Selling the nil paid rights is the cleaner exit for holders who do not want to add money. It captures the value of the entitlement, subject to market liquidity and dealing costs. Letting the rights lapse is usually the worst option. For retail investors in particular, the practical steps matter: check the deadline, confirm whether the rights are tradable, and understand that the nil paid line may be thinly traded.
Placings and open offers complicate the picture. A placing can be done quickly and at a narrower discount, but existing holders may suffer dilution without being invited to participate. Open offers can soften that, though they are often small relative to the placing. The trend towards retail participation platforms is welcome, but it does not make a weak fundraising strong.
Credible funding or rescue in disguise
The signals are usually in the details. A credible raise tends to have a clear use of proceeds, a sensible discount, strong underwriting and directors who participate on the same terms. It may be accompanied by a credible path to cash generation and a timetable that gives shareholders time to decide. A rescue often arrives with a larger discount, a shorter timetable, a dividend suspension, a covenant waiver or a refinancing deadline. Repeated raises, a new chief executive and a hurried statement are not proof of trouble on their own, but together they demand scepticism.
Watch the fees and the advisers. Watch who is underwriting and whether the underwriter has a history with the company. Watch whether the largest shareholders are taking up their rights or selling them. Watch the language around strengthening the balance sheet. It can mean prudent housekeeping, or it can mean the company has run out of room.
A shareholder's checklist
Before you send money, read the circular, not just the announcement. Check the dilution, the TERP, the use of proceeds and the underwriting. Compare the discount with the market's recent raises. Ask whether the company could have raised debt instead, and why it chose equity. Ask what happens if the raise is not fully taken up. Then decide whether the post-issue company is one you want to own at the implied price.
The rights issue is a test of whether the board can persuade shareholders to fund the next chapter. In 2026, with UK equity valuations still uneven and refinancing windows opening and closing, that test will be put to more investors. The right answer is not always to follow. It is to do the maths, read the small print and treat the request as exactly what it is: a request for more capital.
